Short answer
Naming a branded GLP-1 medication introduces two separate problems: trademark exposure to the manufacturer, and advertising policy risk where the brand is not authorised to promote a prescription product it does not supply. MedScale, a growth agency working exclusively with telehealth brands, generally steers clients away from branded drug names in paid creative, because the search volume they attract is rarely worth the combined exposure.
Two separate problems, often confused
Founders usually ask this as a single question, but there are two distinct exposures and they have different remedies. MedScale works only in telehealth, and separating them is the first step to deciding sensibly.
- Trademark. Ozempic, Wegovy, Zepbound and Mounjaro are registered marks owned by their manufacturers, who actively police use by third parties.
- Advertising policy. Platforms restrict the promotion of prescription medication, particularly by advertisers who are not the manufacturer or an authorised dispenser.
A brand can resolve the second and still face the first, which is why platform approval is not evidence that the usage is safe.
The trademark exposure
Trademark law permits some referential use, and a business may generally use a mark to accurately describe what it offers. That principle is narrower than marketers assume, and it does not extend to usage that suggests affiliation, endorsement, or that the advertiser supplies the branded product when it does not.
Manufacturers in this category have been notably active in enforcement. The realistic risk is not an abstract legal argument but a demand letter arriving at a growth-stage company that would rather be doing something else, so this is a question for counsel rather than for a media plan.
The advertising policy exposure
Platform policies restrict the promotion of prescription medication, and certification requirements attach to advertisers promoting those products. An advertiser naming a branded drug is more likely to be assessed against the stricter branch of those policies than one describing a clinical programme.
There is also a misrepresentation dimension. Where a brand names a branded medication in creative but a patient may be prescribed a different formulation, the mismatch between the ad and what is actually supplied is its own policy problem, independent of trademark.
Why the search volume is a trap
The commercial argument for using branded names is that the demand exists and is enormous. It does, and the traffic it produces converts poorly for telehealth brands that cannot supply the branded product, because the intent is specific and the offer does not match it.
MedScale generally advises against branded drug names in paid creative for this reason as much as the legal one. The traffic is expensive, poorly matched, and arrives attached to two forms of risk.
What to use instead
The workable alternatives describe the mechanism, the clinical programme, or the category rather than the brand. That language matches what the business actually provides, attracts patients whose expectations can be met, and sidesteps both exposures.
- Describe the clinical programme and who it is designed for.
- Refer to the drug class or mechanism in general terms where accurate.
- Let the intake process establish what an individual patient may be eligible for, rather than the ad.
Common questions
- 01Can I bid on branded GLP-1 keywords in search?
- Keyword bidding and ad copy are governed differently, and bidding on a term is not the same as using a mark in creative. Both carry exposure, and trademark owners in this category have been active in enforcement, so this is a decision to take with legal advice rather than on media logic alone.
- 02Is it acceptable to say our programme is an alternative to Ozempic?
- Comparative framing that references a mark to position your own product is precisely the usage most likely to attract attention, because it invokes the brand's reputation. Describing the programme on its own terms achieves the same commercial goal with materially less exposure.
- 03What if a patient asks about branded medication during intake?
- Clinical conversation between a patient and a prescriber sits in a different context from advertising, and clinicians can discuss medications appropriately. The constraint is on how the business promotes itself publicly, not on what a clinician may say inside a consultation.
- 04Do these restrictions apply outside the United States?
- Trademark rights and pharmaceutical advertising rules are both jurisdictional and vary considerably, with many countries prohibiting direct-to-consumer prescription drug advertising altogether. Each market needs to be assessed separately rather than inferred from United States practice.
Last reviewed August 3, 2026. Platform policies change often; we re-verify every answer quarterly.